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1. Summary
The transforming growth factor b (TGFb) signalling pathway plays a central
role during embryonic development and in adult tissue homeostasis. It
regulates gene transcription through a signalling cascade from cell surface
receptors to intracellular SMAD transcription factors and their nuclear cofac-
tors. The extent, duration and potency of signalling in response to TGFb
cytokines are intricately regulated by complex biochemical processes. The cor-
ruption of these regulatory processes results in aberrant TGFb signalling and
leads to numerous human diseases, including cancer. Reversible ubiquitylation
of pathway components is a key regulatory process that plays a critical role in
ensuring a balanced response to TGFb signals. Many studies have investigated
the mechanisms by which various E3 ubiquitin ligases regulate the turnover
and activity of TGFb pathway components by ubiquitylation. Moreover,
recent studies have shed new light into their regulation by deubiquitylating
enzymes. In this report, we provide an overview of current understanding of
the regulation of TGFb signalling by E3 ubiquitin ligases and deubiquitylases.
2. The transforming growth factor b signalling pathway
The transforming growth factor b (TGFb) family of cytokines control a plethora
of cellular processes, including proliferation, differentiation, extra-cellular
matrix production, motility and survival [1,2]. These translate into critical
tissue functions throughout embryogenesis and adult life, achieved by striking
a balance between proliferation and differentiation [2–4]. When this balance is
perturbed, the TGFb pathway malfunctions. Aberrant TGFb signalling is
associated with many human diseases including immune disorders, fibrosis,
cancer progression and metastasis [5–12]. Therefore, understanding the mol-
ecular mechanisms underpinning the regulation of the TGFb pathway would
facilitate novel therapeutic opportunities against these diseases.
TGFb signalling is initiated when ligands bind to their cognate receptors
(figure 1). There are at least 42 different TGFb ligands, which are divided
into two main subgroups: the TGFb family and the bone morphogenetic
protein (BMP) family. Ligand binding induces specific quaternary complex for-
mation of the transmembrane serine threonine kinase receptors. These receptors
are divided into type I (ALK1-7) and type II (ACVR-IIA, ACVR-IIB, BMPR-II,
AMHR-II and TGFbR-II). SMAD proteins are the intracellular transducers of
the pathway; they are divided into specific subgroups: receptor-regulated
(R-SMADs; 1–3, 5 and 8), the co-SMAD (4) and the inhibitory (I-) SMADs
(6 and 7). Upon ligand binding, the type II receptors phosphorylate and activate
the type I receptors. Activated type I receptors phosphorylate the R-SMADs at
their C-terminal SXS motif. This induces R-SMAD complex formation with
SMAD4 and nuclear translocation, where along with their nuclear cofactors
& 2012 The Authors. Published by the Royal Society under the terms of the Creative Commons Attribution
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author and source are credited.they bind DNA and regulate transcription. The vast number of
ligands and receptors allows for the formation of unique
ligand–receptor complexes in distinct biological settings. In
general, the TGFb receptor subfamily signals through SMADs
2 and 3, while the BMP subfamily signals through SMADs 1,
5 and 8, although some crosstalk between the two pathways
has been reported. A negative feedback loop is created
by TGFb- or BMP-induced transcription of the I-SMADs.
I-SMADs inhibit the pathway by competing with R-SMADs
for association with the type I receptors, or by recruiting E3
ubiquitin ligases and targeting the receptors for degradation.
In the nucleus, a variety of nuclear cofactors are required for
the R-SMADs to bind DNA and induce gene transcription
(figure 1). Additionally, various histone and DNA modifiers
are required for opening or closing sections of DNA to tran-
scriptional regulation by R-SMADs [1,13–18]. While we focus
on the role of reversible ubiquitylation in regulating the core
components of the TGFb pathway in this review, they can be
further regulated by multiple post-translational modifications,
which also impact the outcome of TGFb signalling. Often it is
the integration of all the regulatory inputs that determines the
cellular responses to TGFb signals.
3. Reversible ubiquitylation
Ubiquitylation, also referred to as ubiquitination, is a reversible
process by which ubiquitins are attached to proteins, either
singly or in chains. This post-translational modification
causes target proteins to undergo changes in stability,
subcellular localization or activity. Ubiquitin is a member of a
conserved family of small eukaryotic proteins (approx.
8.5 kDa)that sharetheubiquitinfoldstructure.Throughaniso-
peptide bond, ubiquitin is attached to lysine residues on the
target, creating mono-ubiquitylated proteins. Attaching more
ubiquitin molecules to the lysines of an already protein-
bound ubiquitin creates polyubiquitin chains. Depending on
which lysine the subsequent ubiquitin molecules are attached
to, different fates await the polyubiquitylated proteins. While
eight linkage types are possible (through K6, K11, K27, K29,
K33, K48, K63 and a-amino group of ubiquitin) as well as
mixed chains, not all have beenattributed afunction.Twolink-
age types are commonly studied and reported in the TGFb
pathway: K48 chains are known to signal protein degradation,
while K63 chains play a role in signalling as well as in protein
trafficking and endocytosis.
Ubiquitin attachment is achieved through a three-step
process catalysed by an E1-ubiquitin-activating enzyme,
specific E2-ubiquitin-conjugating enzymes and a wide array
of E3-ubiquitin ligases. E1 enzymes activate and transfer
ubiquitin in an ATP-dependant manner to the E2-ubiquitin-
conjugating enzyme. This high-energy ubiquitin–E2
conjugate then specifically interacts with the E3-ubiquitin
ligase, which could be either a single protein or part of a
larger ligase complex. E3s can be divided into three structural
groups, U-Box, HECT and Ring E3s, depending on their con-
served domains and mode of catalysis. Several ubiquitin-like
proteins (UBLs), including SUMO1-3, NEDD8, FUBI, HUB1,
ISG15, FAT10, URM1, UFM1, Atg12 and Atg8, share a similar
three-step attachment process. However, these UBLs use
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Figure 1. The logic of TGFb signalling from the membrane to nucleus. Upon ligand binding, the TGFb/BMP receptor kinases mediate the phosphorylation of
R-SMADs. R-SMADs are depicted showing their MH1/Linker/MH2 domains. This induces the association of R-SMADs with SMAD4 and their nuclear translocation. In
the nucleus, the SMADs form transcription complexes with multiple cofactors and regulate the transcription of multiple target genes. Most of the known
transcriptional cofactors of SMADs are indicated, although not all are described in the text.
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2differentE1,E2andE3enzymes.WhileSUMO(smallubiquitin-
like modifier) has been reported to modulate TGFb signalling,
this review will concentrate on ubiquitin [19–24].
The removal of ubiquitins or polyubiquitin chains from the
target protein is catalysed by deubiquitylating enzymes
(DUBs). Therefore, DUBs reverse the function of E3 ubiquitin
ligases [25]. DUBs remove ubiquitin from cellular adducts,
process inactive ubiquitin precursors, proofread ubiquitin–
protein conjugates and protect the 26S proteasome from ubi-
quitin chain accumulation [26]. Furthermore, DUBs generate
free ubiquitin by removing and chopping ubiquitin chains
from proteins, leading to recycling of ubiquitin, thereby contri-
buting to ubiquitin homeostasis. The fate of ubiquitylated
proteins canbe further modified by DUBsthat edit or trim ubi-
quitin chains, resulting in a reversal of ubiquitin signalling.
This could lead to protein stabilisation by rescue from degra-
dation [25]. Deubiquitylation is implicated in several cellular
functions such as gene expression, DNA repair, cell cycle
regulation, kinase activation and microbial pathogenesis [27].
DUBs are classified into five distinct functional and
structural groups: the zinc metalloproteases JAMM/MPNþ,
and the cysteine proteases, comprised of ubiquitin C-terminal
hydrolases (UCHs), ubiquitin-specific proteases (USPs), ovar-
ian tumour proteases (OTUs) and Josephins [25]. There are
also DUBs that resemble the adenovirus protease that cleave
interferon-stimulated gene 15 (ISG15) conjugates and ubiqui-
tin-like proteases (ULPs), which belong to the Adenain
family of cysteine proteases, that are specific to ubiquitin-like
proteins SUMO or NEDD8 [27]. As the human genome
encodes less than 100 DUBs, it is evident that DUBs are
highlyregulatedandplayaroleindiversesignallingpathways
in order to oppose the action of over 600 E3 ligases [25,28].
A combination of substrate and target choice determines
overall DUB specificity, which is further regulated by confor-
mational/post-translational changes, subcellular localization
and interactions with cofactors. DUBs distinguish between
ubiquitin-like molecules, isopeptides, linear peptides and
different types of ubiquitin linkage and chain structures as
well as exo- versus endo- deubiquitylation to ensure specificity.
Enzymatic activity of DUBs is often cryptic and regulated by
occluding the substrate-binding site of certain DUBs or
by inducing conformational changes that activate the catalytic
site. Apart from these substrate-induced conformational
changes and post-translational covalent modifications, activity
can also be regulated by interacting cofactors. Other events,
such as transcriptional regulation of DUB expression and sub-
cellular localization, further ensure specific ubiquitin chain
cleavage. DUBs are modular and contain multiple domains
that mediate protein–protein interactions, apart from their
catalytic domains. These domains include ubiquitin-binding
domains (UBDs) or ubiquitin-like folds (UBL folds), ubiquitin-
interacting motifs (UIMs), zinc finger USP domains (ZnF-UBP
domain) and ubiquitin-associated domains (UBA domains).
These domains contribute to the binding and recognition of
different ubiquitin chain linkages but some DUBs also display
direct affinity for their ubiquitylated target protein [25,27,28].
Recent studies have demonstrated that DUBs play critical
roles in the TGFb pathway regulation [7,29,30]. However, the
field requires further research in order to identify DUBs that
regulate the TGFb pathway and understand their mode of
action. Understanding the precise roles of DUBs in regulating
the TGFb pathway may unravel new opportunities for
therapeutic intervention.
4. Regulation of the TGF b
pathway components by reversible
ubiquitylation
The fundamental steps and the key players in the TGFb path-
way are generally well defined. In this review, we focus on
our understanding of how reversible ubiquitylation impacts
three groups of key TGFb pathway mediators: the TGFb
receptors, the SMAD transcription factors and nuclear
SMAD cofactors. By integrating multiple signals, reversible
ubiquitylation of these components in different biological
contexts plays crucial roles in balancing the outcome of
TGFb signalling. Defective ubiquitylation of the TGFb path-
way components has been implicated in many human
diseases, especially cancer [7,8,11,12,31–34].
5. Reversible ubiquitylation of TGF
b receptors
Receptor complex assembly and activation upon binding
TGFb ligands are central to the activation of intracellular sig-
nalling. The activity and integrity of type II and type I TGFb
receptors can be modulated by several strategies: depho-
sphorylation of the activated receptors, interfering with the
receptor/R-SMAD binding, changing receptor localization
and/or targeting receptors for proteasomal degradation.
I-SMADs play a crucial role in some of these strategies by
modulating the activity and stability of active TGFb receptor
complexes. SMAD7 was reported to inhibit the TGFb path-
way by not only interfering with R-SMAD phosphorylation
but also recruiting the E3 ubiquitin ligases SMURF1 and
SMURF2 to the receptor complex (figure 2) [35,36]. This led
to both receptors (ALK5 and TGFbR-II) and SMAD7 being
ubiquitylated and targeted for degradation. Similarly,
SMAD6/7 has been described to direct SMURF1 to ALK6
and mediates receptor ubiquitylation and degradation [37].
Both I-SMADs and SMURF1/2 are transcriptional targets of
TGFb and BMP signals, thereby creating a negative feedback
loop [38,39]. A glycosyl phosphatidylinositol-anchored
protein, CD109, further enhances the SMAD7–SMURF2
receptor complex interaction, strengthening the negative
feedback [40,41]. Conversely, a recent study demonstrated
that a protein named TGF-b-stimulated clone 22 (TSC-22),
which is induced by TGFb, inhibits the SMAD7–SMURF
complex from binding, ubiquitylating and degrading the
receptor complex. As expected, this leads to enhanced
TGFb signalling that translated physiologically into increased
TGFb-induced cellular differentiation [42]. Tribbles homol-
ogue 3 (TRB3) is another TGFb-induced gene capable of
enhancing pathway signalling in a positive feedback loop.
TRB3 enhances SMAD3 nuclear localization and induces
degradation of SMURF2 promoting cell migration, invasion
and epithelial to mesenchymal transition (EMT) [43].
Inhumanrenalcell carcinomas,enhancedSMURF2expression
causes the reduction in levels of type II TGFb receptor by pro-
teasomal degradation [8]. SMURF1andSMURF2belongto the
NEDD4-like family of HECT E3 ubiquitin ligases and are
characterized by the presence of a conserved C2-WW-HECT
domain structure [44]. While the C2 domain regulates the sub-
cellular localization, the WW domains are 38–40 residue
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3motifscharacterizedbytwohighlyconservedtryptophansand
folded as a three-strand b sheet that associate with the proline-
rich‘PPXY’motif(alsoknownas‘PY’motif) [45].ThePYmotif
present in the linker region of SMAD7 interacts with one of the
WW domains of SMURF1/2 [35]. Other members of the
NEDD4-like family, WWP1 and NEDD4L, have also been
shown to interact with SMAD7 and target ALK5 for ubiquity-
lation and degradation. However, unlike SMURF1/2, they did
not target SMAD7 itself for ubiquitin-mediated degradation,
possiblyprovidingastrongerand longer lastingnegativeregu-
lation of the pathway [46–48]. In our studies, we have
identified three further members of the NEDD4-like family of
E3s, namely NEDD4, WWP2 and ITCH, as SMAD6/7 interac-
tors.Thesearealsolikelytoactinasimilarmodetoregulatethe
activity and stability of the TGFb receptors. The precise nature
of ubiquitin attachment and the sites for ubiquitylation on
TGFb receptors remain undefined. While several E3s have
been implicated to act on the TGFb receptors, to date very
few E2-ubiquitin-conjugating enzymes have been assigned.
SMAD7 has been reported to facilitate the recruitment of
UbcH7, an E2 enzyme, to SMURF2 thereby providing a
pathway-specific control on SMURF2 activity [49].
The regulation of TGFb receptors by DUBs would be pre-
dicted to reverse the effects of E3 ubiquitin ligases and
positively regulate the TGFb pathway. To date, only two
studies have addressed deubiquitylation of the receptors.
UCH37 was reported to target ALK5 for deubiquitylation
thereby enhancing TGFb signalling [50]. However, structural
studies on the UCH family of DUBs imply they are di- or
polyubiquitin chain editors [25]. USP15 was identified as a
modulator of TGFb-induced transcription from a pan DUB-
siRNA screen and subsequently shown to act on ALK5. The
study further linked USP15 gene amplification with poor
prognosis in glioblastoma [7].
6. Regulation of SMAD transcription factors
by reversible ubiquitylation
SMAD proteins are the intracellular transducers of TGFb sig-
nals. R-SMADs are phosphorylated at their C-terminal SXS
motif inducing complex formation with SMAD4 and nuclear
translocation. In the nucleus, they induce transcriptional
responses of TGFb target genes. Interfering with R-SMAD
phosphorylation, stability, R-SMAD/SMAD4 complex
formation or DNA binding would negatively impact TGFb
pathway signalling. Reversible ubiquitylation of SMADs
directly impacts one or more of these attributes. Here, we
provide an overview of how reversible ubiquitylation of
SMAD transcription factors impacts SMAD function and
pathway signalling. Figure 3 summarizes the key players
regulating reversible ubiquitylation of SMADs.
7. The BMP pathway SMADS
The first E3 ligase reported to ubiquitylate BMP-responsive
SMADs was SMURF1 [51]. The WW domain of SMURF1
interacts with the PY motif of SMAD1/5 and targets them
for ubiquitylation and proteasomal degradation [51,52].
Studies in Xenopus embryos showed that SMURF1 causes
dorsalization of ventral mesoderm and neuralization of ecto-
derm, phenotypes consistent with inhibition of the BMP
pathway [51]. SMURF1-mediated SMAD1/5 ubiquitylation
promotes myogenic differentiation of C2C12 cells, blocks
BMP-2-mediated osteogenic conversion [52] and modulates
the effects of BMP4 on embryonic lung growth [53]. In con-
trast, SMURF1 has been shown to have little effect on
TGFb-inhibited myogenic differentiation [51,52]. LMP-1,
an LIM domain protein capable of inducing de novo bone
formation that contains a WW domain, interacts with
SMURF1 and competes with SMAD1/5 for binding . Conse-
quently, LMP-1 prevents SMURF1-mediated SMAD1/5
ubiquitylation and results in increased cellular responsive-
ness to BMP signals [54]. The PY motif in SMAD1/5 is
preceded by a cluster of Ser/Thr residues. Phosphorylation
of these residues, catalysed by proline-directed Ser/Thr
protein kinases (e.g. MAP kinases and CDK8/9), in response
to different stimuli as well as glycogen synthase kinase-3
(GSK-3) is essential for its interaction with SMURF1 [55–
57]. BMP-induced sequential linker phosphorylation of
SMAD1 by CDK8/9 and GSK-3 primes SMAD1 for
transcriptional action and degradation, respectively. While
phosphorylation by CDK8/9 induces recruitment of YAP1
mediator through its WW domain, subsequent phosphoryl-
ation by GSK-3 displaces YAP1 and recruits SMURF1
[45,55]. YAP1 stability is further regulated by SCF (Skp,
Cullin, F-box)–bTRCP-induced ubiquitylation [58]. These
studies demonstrate a clear interplay between phosphorylation
and ubiquitylation in balancing the outcome of BMP pathway
I-SMAD,
SMURF1/2, WWP1, NEDD4L
UCH37, USP15
PP
downstream
signalling
degradation
no signalling
U
U
U U
Figure 2. Regulation of the TGFb–BMP receptor complexes by reversible ubiquitylation. Sketch of how reversible ubiquitylation of the receptor complexes may
regulate pathway signalling. Detailed description is covered in the text.
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4signalling. SMURF2 has also been shown to polyubiquitylate
SMAD1 and mediates its degradation. Studies in Xenopus
embryos confirmed that SMURF2 inhibits SMAD1 responses
[59,60]. SMAD8 lacks the PY motif in its linker region
and would be predicted to be resistant to SMURF-mediated
ubiquitylation and degradation. A U-box-dependent E3 ubiqui-
tin ligase member carboxyl terminus of Hsc70-interacting
protein (CHIP) was reported as an interactor of SMAD1. CHIP
was shown to cause ubiquitylation and degradation of SMAD1,
resulting in the inhibition of the BMP-induced transcriptional
activity [61]. The lysine residues within BMP–SMADs modified
by ubiquitylation, the nature of polyubiquitin linkages and
the E2-ubiquitin-conjugating enzymes involved remain to be
defined. No DUBs for BMP–SMADs have been reported.
8. The TGF b pathway SMADs
Among the SMADs, TGFb–SMAD ubiquitylation has
received the most scrutiny. The evidence for polyubiquityla-
tion and degradation of TGFb-induced phospho-SMAD2 was
first demonstrated in 1999 [62]. Subsequently, several E3 ubi-
quitin ligases, including SMURF1/2, NEDD4L and WWP1,
have been implicated in mediating the polyubiquitylation
and degradation of SMAD2/3 [47,48,59,63]. These NEDD4-
like E3 ubiquitin ligase members all use the PY motif present
in the SMAD2/3-linker for interaction. However, the recruit-
ment of NEDD4L to SMAD2/3 requires the phosphorylation
of the linker region mediated by CDK8/9 as well as the PY
motif [64]. A WW-domain-containing protein PIN1 has been
implicated in recruiting SMURF2 to linker-phosphorylated
SMADs[65].NEDD4Litselfisalsosubjecttofurtherregulation
by serum/glucocorticoid-regulated kinase 1 (SGK1), which
is itself a transcriptional target of TGFb signalling [64]. Signal
termination is also achieved by other E3 ligases, independent
of linker phosphorylation, using SMAD2/3 interactions with
transcriptional cofactors. The ROC1–SCF–bTRCP RING E3
ligase complex targets activated SMAD3 for nuclear export
and ubiquitin-mediated degradation upon its association
with the transcriptional co-activator p300 [66] . The transcrip-
tional regulator TAZ, reported to be required for SMAD2/3/
4 complex nuclear accumulation, is also regulated by SCF–
bTRCP-induced ubiquitylation and degradation [67,68].
While the previous examples show SMAD2/3 regulation
after TGFb signal initiation, CHIP has been shown to interact
with ubiquitylate and degrade basal SMAD3 levels, resulting
in the inhibition of TGFb signalling [69].
SMURF2 features prominently in reports describing
SMAD2/3 degradation. SMURF2-mediated inhibition of
TGFb signalling has been demonstrated across multiple
organisms and in obstructive nephropathy [34,39,65,70].
One area of contention is whether SMURF2 polyubiquitylates
[39,65,70] or monoubiquitylates [34] the TGFb SMADs,
targeting them for degradation or inhibiting complex forma-
tion with SMAD4, respectively. Nonetheless, both outcomes
are reported to result in TGFb signalling inhibition.
A member of the RING E3 ubiquitin ligase family, ARKA-
DIA, was initially reported to ubiquitylate phosphorylated
SMAD2/3 in the nucleus [71]. Despite this, ARKADIA
resulted in enhanced TGFb signalling. While counterintui-
tive, this was consistent with previous reports showing the
effect of ARKADIA on Nodal signalling [72,73]. It was later
shown that ARKADIA targets the inactive phospho-
SMAD2/3-SKI complex for ubiquitylation and degradation
SMURF2
other E3s
DUBs?
DUBs?
E3s?
DUBs?
pSMAD2/3, E3s
DUBs?
P300/SCF
DUBs?
SMAD6, SMURF1
ARKADIA
other E3s
P300/CYLD
D
U
B
s
?
S
M
U
R
F
1
,
N
E
D
D
4
L
SCPs
MAPKs/CDKs,
GSK-3
USP15
USP9x
TRIM33
SMAD4 SMAD transcription complex
TRIM33
SMURF2
R-SMAD
TFs
Ski/SnoN Ski/SnoN
TFs
Runx2
I-SMAD I-SMAD
Runx2
TRIM
33
SMAD4
SMAD2/3 R-SMAD SMAD4
R-SMAD R-SMAD
R-SMAD R-SMAD R-SMAD
R-SMAD
SMAD4 SMAD4
R-SMAD R-SMAD
U
U
U
U
U
U
U
U
U
U
U
U
U
U
U
U
U
U
U
U
U
U
U
U
U
U
U
U
U
U
P P P
P
P P
P P P
P
P
P
Figure 3. Regulation of SMAD transcription factors and nuclear cofactors by reversible ubiquitylation. An overview of how reversible ubiquitylation of SMAD transcription
factorsand associatednuclearcofactorsmayimpacttheSMAD-dependenttranscription.MostofthereportedE3sand DUBs known toregulate specificproteinsareincluded.
The reported mechanisms by which different E3 ubiquitin ligases and DUBs regulate SMAD proteins and associated cofactors are described in the text.
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5[74]. SKI is a nuclear cofactor that negatively regulates TGFb
signalling by binding phosphorylated SMADs and prevent-
ing their transcriptional activity. ARKADIA balances SKI
and SMAD2/3 ubiquitin-mediated degradation enhancing
pathway transcriptional responses while terminating signal-
ling once that is achieved. Changing the balance leads to
TGFb-pathway-related pathology in colorectal cancer where
mutations leading to a reduction in ARKADIA function
have been reported [11]. WWP1/2 have also been implicated
in ubiquitylation and destabilization of SMAD2/3 [48,75].
WhileITCHand CBLB E3ubiquitinligaseshavebeen reported
to ubiquitylate SMAD2, they promote TGFb-induced SMAD2
phosphorylationandsignalling[76–78].AlthoughITCHmed-
iatestheattachmentofK48-linkedubiquitinchainsonSMAD2,
no degradation is observed [77]. This indicates that certain
K48-linked polyubiquitin chains may have functions beyond
proteasome-mediated degradation.
Despite numerous E3 ubiquitin ligases proposed to
ubiquitylatetheTGFbSMADs,USP15istheonlydeubiquitylase
reported to act on SMAD2/3 [30]. USP15 has been reported
to reverse SMAD2/3 monoubiquitylation, which targets the
DNA-binding domains of SMAD2/3 and inhibits promoter
recognition. The DUBs reversing the polyubiquitylation of
SMAD2/3 remain to be defined.
9. SMAD4
Association of SMAD4 with R-SMADs is a critical step in the
canonical TGFb and BMP signalling pathways. Preventing
this association or targeting SMAD4 for degradation inhibits
TGFb/BMP signalling. Regulation of SMAD4 by both mono-
and polyubiquitylation has been reported [61,79–84]. Despite
the lack of an intact PY motif, SMAD4 is polyubiquitylated by
SMURF1/2, WWP1 and NEDD4L, which are recruited to
SMAD4 by their association with I-SMADs and SMAD2
[83]. The E3 ligase CHIP has been implicated in controlling
SMAD4 stability; however its role in SMAD4 ubiquitylation
is unclear [61]. SCF complexes have been reported to ubiqui-
tylate and degrade SMAD4. b-TRCP1 was initially shown to
bind SMAD4 and induce its ubiquitin-mediated degradation
through SCF. In the absence of SMAD4, the over-expressed
complex was unable to inhibit TGFb-induced cell cycle
arrest [84]. SCF–bTRCP1 complex has been reported to con-
trol SMAD4 stability in pancreatic cancer cells [12]. The other
SCF complex with SKP2 was also shown to bind and degrade
SMAD4 [82]. Interestingly, TGFb induces destruction of SKP2
in the nucleus, providing a further layer of control in the feed-
back loop [81].
The RING E3 ubiquitin ligase TRIM33 (also known as Ecto-
dermin/TIF1g), which also contains a plant homeodomain
(PHD)—Bromo domain, has been proposed to interact with
and ubiquitylate SMAD4 [80]. Although the critical role of
TRIM33 on the TGFb pathway is not debated, reports on the
mechanisms by which it achieves this differ greatly. Two
modes of action have been proposed. (i) TRIM33 interacts
with phosphorylated SMAD2/3 in competition with SMAD4,
therebyinterferingwithSMAD2/3–SMAD4bindingandcreat-
ing separate SMAD2/3–SMAD4 and SMAD2/3–TRIM33
complexes, each resulting in distinct functions on cellular pro-
cesses [85,86]. Furthermore, the PHD-Bromo domain has been
demonstrated to be essential for the recruitment of TRIM33 to
chromatin [79,86]. (ii) TRIM33 directly interacts with SMAD4
and not SMAD2/3, catalyses its polyubiquitylation [80] or
mono-ubiquitylation at Lys519, which inhibits SMAD2/3–
SMAD4 complex formation [29]. It has been shown that chro-
matin binding is required for the E3 ligase activity of TRIM33
in vitro [79]. While targeted disruption of the TRIM33 gene in
mice has established the role for TRIM33 in limiting Nodal
responsiveness in vivo [87], it has not resolved the debate on
its mode of action. A mouse or a cell-line model in which
wild-type TRIM33 is replaced by a catalytically inactive
mutant with an intact PHD-Bromo domain would resolve defi-
nitivelytheissueofwhethertheE3ligaseactivityofTRIM33on
SMAD4 is necessary for its influence on the TGFb pathway.
USP9X/FAM is the only deubiquitylase reported to
reverse the monoubiquitylation of SMAD4 at Lys519
mediated by TRIM33 [29]. Depletion of USP9X resulted in
inhibition of TGFb-induced transcriptional and cellular
responses but not phospho-SMAD3. USP9X interacted with
and deubiquitylated SMAD4 [29].
10. Inhibitory SMADs 6/7
In the light of multiple reports on the inhibitory effects of
I-SMADs, inducing I-SMAD polyubiquitylation and degra-
dation would be predicted to strongly enhance TGFb/BMP
pathway signalling. Although SMAD6/7 interact with the
majority of NEDD4-like E3 ubiquitin ligases through their PY
motif, these E3s primarily employ SMAD7 as an adaptor to
target various substrates, including the TGFb/BMP receptors.
In the process, I-SMADs are often destroyed by proteasomal
degradation [35,36]. ARKADIA, an E3 ligase that does not
target the receptor complex, has been shown to target
SMAD7 for ubiquitylation and degradation, thereby enhan-
cing pathway signalling [88,89]. ARKADIA also targets
multiple components of the TGFb pathway for ubiquitylation
and degradation [11,65,71,74,90–93]. However, selective
SMAD7polyubiquitylationanddegradationhasbeenreported
in renal fibrosis and hypertension mouse models, causing
enhanced pathway signalling [31,94].
Inhibition of I-SMAD ubiquitylation and subsequent
degradation would provide a clear way to negatively control
the TGFb pathway. The histone acetyl transferase, p300, has
been reported to acetylate SMAD7 at Lys64 and Lys70, the
same residues in which ubiquitylation occurs. This prevents
SMAD7 from being targeted by E3s for ubiquitylation and
degradation [95,96]. It has also been reported that the de-acet-
ylase SIRT1 can reverse this, creating an acetylation/
de-acetylation balance controlling SMAD7 fate [97,98].
The only DUB reported to target the I-SMADs is CYLD
[99]. The study performed in CYLD-knockout mice reported
that CYLD targets SMAD7 protein for deubiquitylation and
inhibits TGF-b signalling in the development of regulatory
T cells. Moreover, CYLD appears to deubiquitylate SMAD7
at Lys360 and Lys374 but not at Lys64 or Lys70 [99].
11. Regulation of nuclear SMAD cofactors
by reversible ubiquitylation
Once the activated R-SMAD–SMAD4 complex is transloca-
ted into the nucleus, it must then bind promoter sequences
to positively or negatively regulate the expression of TGFb
response genes. However, SMAD proteins on their own
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6have low DNA-binding affinity and require other cofactors
for DNA binding [16]. Additionally, as previously described,
some nuclear adaptor proteins actually inhibit SMAD–DNA
binding, thereby negatively regulating SMAD transcriptional
activity. Therefore, reversible ubiquitylation of nuclear co-
factors can modulate TGFb-induced transcriptional activity.
RUNX2 is a transcription factor that promotes R-SMAD/
DNA binding in the BMP pathway. SMURF1 has been
reported to induce its ubiquitylation and degradation [100].
SMURF1 is recruited to RUNX2 by its association with
SMAD6 [101]. Most other reports have concentrated on the
regulation of negative nuclear cofactors SKI and SnoN that
antagonize SMAD-mediated transcriptional activity. TGFb-
induced SMURF2/SMAD2 binding and targeting of SnoN
release the negative regulation of SnoN on nuclear SMAD
transcriptional activity in both physiological and pathological
pathway signalling [33,102]. ARKADIA is reported to target
both SKI and SnoN for ubiquitin-mediated degradation in a
similar TGFb-dependent fashion, leading to activation of
transcriptional responses [91,92]. Later reports also identify
that SKI ubiquitylation and degradation requires TGFb
signalling and ARKADIA binding to phosphorylated-
SMAD2/3 [74,93]. ARKADIA function is itself regulated by
binding to proteins such as AXIN and RB1CC1 [89,90]. The
anaphase-promoting complex E3 ligase has also been
reported to act in a similar manner by targeting SnoN
[103,104], while the CDC34 E2 targets SKI and SnoN in a
cell-cycle-dependent fashion [105]. Very little is known
about the DUBs that reverse the ubiquitylation of the
earlier-mentioned nuclear SMAD cofactors.
12. Concluding remarks
The TGFb family of cytokines influences the behaviour and
fate of almost every cell type in vertebrates. The cellular
responses to TGFb signals vary greatly depending on the bio-
logical context. Despite this, all cells share the fundamental
transduction mechanisms of TGFb signalling. Various post-
translational modifications of key mediators of the TGFb
pathway in response to multiple signals modulate their
activity, stability and subcellular localization. The integration
of different signals ultimately determines the extent and
duration of cellular responses to TGFb signals. Reversible
ubiquitylation of fundamental TGFb pathway mediators
offers a key regulatory balance on the outcome of the
pathway. Ubiquitylation confers a versatile modification of
target proteins. This versatility is further augmented by the
possibility of multiple types of ubiquitin chains that can be
formed on target proteins. While K48-linked polyubiquitin
chains have been described to cause proteasomal degradation
of TGFb pathway components, the precise nature of polyubi-
quitin chains remains unexplored. Proteins that contain
unique UBDs would be predicted to be essential for inter-
preting the signals contained within target proteins with
unique polyubiquitin chains. In the TGFb pathway, few
such proteins have been identified.
Regulation of the TGFb pathway by ubiquitylation of key
components has been widely reported (table 1). While many
candidate E3 ubiquitin ligases have been proposed, little is
known about the E2-ubiquitin-conjugating enzymes further
upstream. Several members of the NEDD4-like family of E3
ubiquitin ligases have been reported to catalyse the polyubi-
quitylation and degradation of both TGFb receptors and
SMAD transcription factors. Indeed, SMURF1/2 appears to
be transcriptional targets of TGFb cytokines themselves and
inhibit the pathway through a negative feedback loop [18].
The observations that the recognition of SMAD1 and
SMAD2/3, by SMURF1 and NEDD4L, respectively, requires
phosphorylation of linker regions of SMAD proteins imply an
active interplay between phosphorylation and ubiquitylation
processes [57,64]. Such crosstalk is likely to happen across
Table 1. A summary of known E3 ubiquitin ligases and deubiquitylating enzymes (DUBs) involved in TGFb pathway signalling. Asterisks indicate E3s also
targeting tail and/or linker-phosphorylated SMAD proteins. Common alternative names for E3 ubiquitin ligases and DUBs in table: ARKADIA ¼ ring ﬁnger 111;
WWP1 ¼ AIP5, Tiul1; NEDD4L ¼ NEDD4-2; TRIM33 ¼ ECTO, TIF1g;I T C H¼ AIF4, AIP4; USP9x ¼ FAM; UCH37 ¼ UCHL5.
E3 ubiquitin
ligases
ARKADIA 3* 33
SMURF1 33 * 333 3
SMURF2 33 * 3* 33 3
WWP1 33 * 3
NEDD4L 33 * 3
CHIP 333
TRIM33 3
CBLB 3*
SCF-b-TRCP 3* 3
SCF–SKP2 3
ITCH 3
APC 3
TGFb
components receptors
BMP
SMADs
TGFb
SMADs SMAD4 I-SMADs
nuclear
cofactors
DUBs UCH37 3
USP15 33
USP9x 3
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7multiple proteins and post-translational modifications as cells
respond to a constant barrage of complex extra-cellular and
intra-cellular signals. The knockout mouse models of several
E3 ubiquitin ligases implicated in the TGFb pathway exist.
SMURF1 knockout mice show enhanced bone mass upon
ageing, phenotypes expected to result from enhanced BMP
signalling [106]. While functional redundancy between
SMURF1 and SMURF2 may have contributed to the lack of
striking phenotypes in SMURF1- or SMURF2-knockout
mice, double knockout resulted in embryonic lethality with
severe defects in planar cell polarity [34,106,107]. As most
E3 ubiquitin ligases implicated in the TGFb pathway are
likely to have several substrates, observed phenotypes
could be attributed to effects on their most critical targets,
thereby confusing any impact relating to the TGFb pathway.
Pathway-specific E3 mutants would therefore be required for
such physiological studies relating to one pathway over any
others targeted by E3 ligases. Understanding the molecular
mechanisms by which the E3 ubiquitin ligases recognize
specificsubstrates,andhowtheyareactivated,wouldbeessen-
tial to producing such pathway-specific physiological mouse
models. The precise mechanisms by which all reported E3 ubi-
quitin ligases are activated or recognize their substrates in the
TGFb pathway are still not well defined.
Deciphering the mechanisms of how TGFb receptor
kinasesmediatethephosphorylation ofR-SMADshasresulted
in our understanding of the fundamental aspects of TGFb sig-
nalling [1]. The precise ubiquitylation sites within receptors,
SMAD proteins or SMAD cofactors as well as the nature of
polyubiquitin chains that are attached to the initial ubiquitin
arelargely undefined. Most ofthe ubiquitylation sitesreported
on SMAD proteinsthus far have resulted from over-expression
and mutagenesis studies, which have the potential of yielding
artefacts. Recent technologies capable of identifying ubiquity-
lated peptides on endogenous proteins hold great promise
for investigating reversible ubiquitylation in the TGFb path-
way [108,109]. Indeed one of these studies was able to
identify multiple ubiquitylation sites within endogenous type
IT G F b/BMP receptors as well as BMP and TGFb ligands.
That the ligands could themselves be regulated by ubiquityla-
tion is an intriguing observation that has as yet eluded
consideration entirely.
Investigation into the regulation of the TGFb pathway by
DUBs is an emerging research field. To date, only three
DUBs, namely UCH37, USP9X and USP15, have been attrib-
uted a role in deubiquitylating components of the TGFb
pathway (table 1) [7,29,30,50]. The mode of substrate recog-
nition and catalysis of reported TGFb pathway DUBs are
still undefined. Because of their limited number in the
genome, DUBs are likely to be promiscuous with regard to
their substrate range. Therefore, RNAi-based global DUB
knockdown strategies employed to identify TGFb pathway
regulators have to be used cautiously. A better strategy
would be to identify DUBs that associate directly with
specific TGFb pathway components. Understanding the mol-
ecular mechanisms by which DUBs recognize their substrates
is critical in defining their roles on specific targets. In addition
to being peptidases, the DUBs possess a characteristic in
being able to recognize and bind to uniquely ubiquitylated
proteins or ubiquitin chains. This ability alone, regardless of
their catalytic activity, may serve an important regulatory
purpose during signalling by modulating the activity, subcel-
lular localization or stability of the target protein. Indeed,
recent reports demonstrate that DUBs influence protein func-
tion independently of their deubiquitylating activity. As an
example, USP7 was demonstrated to increase the binding
affinity of p53 to its target genes independent of its deubiqui-
tylase activity [110]. Similar analogies may hold true for
DUBs in the TGFb pathway.
The TGFb pathway components are frequently com-
promised in numerous diseases, including fibrosis, cancer
progression and metastasis [7,8,11,12,31–34,94]. Therefore,
understanding the molecular mechanisms by which reversible
ubiquitylation regulates TGFb signalling may hold some thera-
peutic promise against these diseases. Amplification of several
members of the NEDD4-like E3 ligases, including SMURF1/2,
is reported to be associated with tumour progression [44].
Reduced ARKADIA activity is associated with the pathogen-
esis of colorectal cancers [11]. The efficacy of the proteasome
inhibitor Bortezomib against B cell lymphoma demonstrates
that ubiquitin ligases and the ubiquitylation system could be
exploited as targets for anti-cancer therapies [111]. DUBs,
which constitute the largest family of peptidases, are also
associated with many human diseases, including cancer and
could make attractive therapeutictargets [7,111,112]. Therefore,
targeting the TGFb-pathway-specific E2-ubiquitin-conjugating
enzymes, E3-ubiquitin ligases or DUBs for inhibition may pro-
vide opportunities for the development of therapies against
diseases in which the TGFb pathway is compromised.
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